Clinical trial · Observational
MMRF Molecular Profiling Protocol
Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies
NCT02884102CI-TRIAL-00089354unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This protocol is now being used as screening for the MyDRUG study
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Plasma Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| genetic sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- actionable mutations report
- timeFrame
- 10-14 days
Secondary outcomes (2)
- measure
- Survival Rates
- timeFrame
- Overall survival
- measure
- Disease Recurrence
- timeFrame
- Time to Progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must have a diagnosis of multiple myeloma or related malignancy 2. Patients are undergoing standard of care bone marrow aspirates 3. Patients (male or female) from any race or ethnicity must be at least 18 years of age at the time of registration. 4. Procedure-specific signed informed consent form prior to initiation of any study-related procedures. Exclusion Criteria: 1. It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo a bone marrow aspirate. 2. Patients who are incarcerated are not eligible to participate. 3. Women who are pregnant 4. Patients who have had another malignancy within the last five (5) years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) where there is a possibility to contaminate the bone marrow aspirate.
References
Publications (0)
Data not yet available
No reference posted for this study.